Table 1 Clinical characteristics
From: Bronchiectasis in renal transplant patients: a cross-sectional study
|  | RT-B n = 19 | IB n = 23 | P value |
|---|---|---|---|
Male | 12 (63) | 11 (48) | 0.320 |
Age, years | 66 (57–69) | 62 (48–70) | 0.147 |
Smoker (current or former) | 12 (63) | 9 (39) | 0.121 |
 Pack-years | 26 (14–30) | 10 (7–25) | 0.652 |
Clinical features | |||
 BMI, kg/m2 | 25 (23–30) | 23 (21–26) | 0.144 |
 Chronic cough | 13 (68) | 22 (96) | 0.034 |
 Dyspnea | |||
  mMRC ≥ 2a | 8 (53) | 9 (39) | 0.768 |
 Hemoptysis | 0 (0) | 2 (9) | 0.215 |
Respiratory tract infections | |||
 Exacerbation in the past year | 12 (63) | 19 (83) | 0.637 |
  Number of episodes per patient | 1 (0–2) | 1 (1–3) | 0.551 |
 Hospitalization for exacerbation in the past year | 6 (32) | 1 (4) | 0.189 |
Cause of end-stage renal disease | |||
 Chronic glomerulonephritis | 4 (21) | NA |  |
 Diabetic nephropathy | 2 (11) | NA |  |
 Autosomal dominant polycystic kidney disease | 6 (32) | NA |  |
 Chronic tubulointerstitial nephritis | 2 (11) | NA |  |
 Unknown cause of end-stage renal disease | 3 (16) | NA |  |
 Other renalb | 2 (11) | NA |  |
Immunosuppressive drugs | |||
 Mycophenolate mofetil | 14 (74) | NA |  |
 Cyclosporine | 8 (42) | NA |  |
 Tacrolimus | 7 (37) | NA |  |
 Azathioprine | 2 (11) | NA |  |
 Oral corticosteroids | 5 (26) | NA |  |
Antibiotic therapy in the last 6Â months | 12 (63) | 15 (65) | 1.000 |
Interval between first RT and first symptoms, yearsc | 11 (1–20) | NA |  |
Interval between first RT and diagnosis of bronchiectasis, yearsc | 12 (2–18) | NA |  |